Phase 3 MajesTEC-9 Trial Shows Survival Benefit With Teclistamab in Multiple Myeloma

Here are the links extracted from the provided HTML:

1. https://clinicaltrials.gov/study/NCT05572515
2. https://clinicaltrials.gov/study/NCT05083169
3. https://www.jnj.com/media-center/press-releases/unprecedented-results-from-the-phase-3-majestec-3-study-support-tecvayli-plus-darzalex-faspro-as-a-potential-standard-of-care-as-early-as-second-line-for-patients-with-relapsed-refractory-multiple-myeloma